Name: 글로벌 시장 동향
SKU: PH8593
Availability: InStock

보고서 요약(국문)

개요
전 세계 알츠하이머병(AD) 치료제 시장은 2023년 36억 달러에 달했으며, 2024년부터 2031년까지 연평균 10.2% 성장하여 2031년에는 78억 2,900만 달러에 이를 것으로 예상됩니다.
알츠하이머병은 노년층에게 발생하는 신경 질환으로, 기억력, 사고력, 행동의 저하를 유발합니다. 이는 일상생활에 지장을 주는 심각한 인지 기능 저하인 치매의 가장 흔한 원인입니다. 이 질환은 뇌에 아밀로이드 플라크와 타우 단백질이 축적되어 정상적인 기능을 저해함으로써 발생합니다. 질병이 진행됨에 따라 환자는 혼란, 기분 변화, 일상생활 수행의 어려움을 경험할 수 있습니다.

알츠하이머병은 노년층에게 영향을 미치는 신경 질환으로, 기억력, 사고력, 행동의 저하를 초래합니다. 시장 동향: 성장 동인 및 제약 요인
알츠하이머병 발병률 증가
전 세계 알츠하이머병 치료제 시장은 특히 평균 수명이 높은 선진국에서 알츠하이머병 발병률이 증가함에 따라 성장하고 있습니다. 이는 효과적인 치료법에 대한 수요 증가로 이어져 관련 연구 개발을 촉진하고 있습니다.
예를 들어, NCBI 2023에 발표된 논문에 따르면 전 세계적으로 2,500만 명 이상이 치매, 특히 알츠하이머병의 영향을 받고 있습니다. 원인은 아직 밝혀지지 않았지만, 흡연, 고혈압, 비만, 당뇨병, 뇌혈관 질환과 같은 혈관 위험 요인 및 질환과 교육, 사회 참여, 신체 활동과 같은 사회심리적 요인이 치매의 발병 과정 및 임상 증상에 영향을 미칠 수 있다는 증거가 있습니다.

다양한 혈관 위험 요인을 관리하고 사회적으로 통합된 생활 방식과 정신적으로 자극적인 활동을 유지하는 데 초점을 맞춘 장기적인 개입은 알츠하이머병을 포함한 치매의 위험을 줄이거나 임상적 발병을 지연시킬 것으로 기대됩니다.
규제 장벽
전 세계 알츠하이머병 치료제 시장은 임상 시험의 높은 실패율, 질병의 복잡성, 규제 장벽 및 높은 비용과 같은 문제에 직면해 있습니다. 저소득 및 중소득 국가에서의 접근성 부족과 기존 치료법의 높은 비용은 질병 유병률 증가로 인한 수요 증가에도 불구하고 시장 성장을 더욱 제한합니다.
시장 세분화 분석
전 세계 알츠하이머병 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

콜린에스테라제 억제제는 알츠하이머병(AD) 치료제 시장에서 약 43.3%의 점유율을 차지했습니다.
콜린에스테라제 억제제는 전 세계 알츠하이머병 치료제 시장의 핵심 구성 요소로서, 경증에서 중등도 AD 환자의 인지 기능과 기억력을 향상시킵니다. 도네페질, 리바스티그민, 갈란타민과 같은 이 약물들은 AD 환자에게서 일반적으로 감소하는 신경전달물질인 아세틸콜린 수치를 증가시킵니다.
이 약물들은 질병을 완치하거나 진행을 멈추지는 못하지만, 증상을 완화하여 환자의 삶의 질을 개선하고 간병인의 부담을 덜어줍니다. 콜린에스테라제 억제제는 효능, 접근성, 그리고 AD 증상 관리에 대한 지속적인 수요로 인해 전 세계적으로 상당한 규모를 자랑합니다. 그러나 향후 더욱 효과적인 새로운 치료법의 개발은 시장 점유율에 영향을 미칠 수 있습니다.

시장 지역별 점유율
북미는 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
북미는 높은 발병률과 우수한 병원 및 연구 센터에 대한 접근성 덕분에 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 미국 식품의약국(FDA)과 캐나다 보건부(Health Canada)는 알츠하이머 치료제의 안전성과 효과를 보장합니다. 이 지역의 높은 의료비 지출과 환자 중심 단체의 지원은 알츠하이머 연구 및 치료의 전반적인 성공에 기여합니다.
예를 들어, 2024년 7월 미국 식품의약국(FDA)은 알츠하이머병 치료를 위해 키순라(Kisunla, 도나네맙-azbt) 주사제를 승인했습니다. 키순라 치료는 임상 시험에서 연구된 대상군과 같이 경도 인지 장애 또는 경도 치매 단계의 환자에게 시작해야 합니다.

시장 세분화
약물 종류별
콜린에스테라제 억제제
도네페질
갈란타민
리바스티그민
NMDA 수용체 길항제
복합제
기타
투여 경로별
경구
비경구
유통 채널별
병원 약국
소매 약국
온라인 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
주요 글로벌 시장 참여 기업으로는 Eli Lilly and Company, Biogen Inc., AstraZeneca PLC, Roche Holding AG, Novartis International AG, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc., H. Lundbeck A/S 등이 주요 기업입니다.
주요 개발 사항
2024년 6월, 에자이와 바이오젠은 중국에서 인간화 항가용성 응집 아밀로이드 베타 단일클론 항체 "레켐비(LEQEMBI)"를 출시했으며, 2024년 1월 알츠하이머병으로 인한 경도 인지 장애 및 경도 알츠하이머병 치매 치료제로 승인받았습니다. 중국은 미국과 일본에 이어 레켐비를 출시한 세 번째 국가입니다.
보고서 구매 이유
약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 알츠하이머병(AD) 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 및 공동 개발 분석을 통해 사업 기회를 식별할 수 있습니다.
모든 세그먼트를 포함한 알츠하이머병(AD) 치료제 시장의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 알츠하이머병(AD) 치료제 시장 보고서는 약 64개의 표, 61개의 그림, 그리고 186페이지 분량으로 구성됩니다.
주요 독자층 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Overview
Global Alzheimer’s Disease (AD) Therapeutics Market reached US$ 3,600 million in 2023 and is expected to reach US$ 7,829 million by 2031, growing at a CAGR of 10.2% during the forecast period 2024-2031
Alzheimer's Disease is a neurological disorder affecting older adults, causing deterioration in memory, thinking, and behavior. It is the most common cause of dementia, a severe cognitive decline that interferes with daily life. The disease is caused by the accumulation of amyloid plaques and tau tangles in the brain, disrupting normal function. As the disease progresses, individuals may experience confusion, mood swings, and difficulty performing daily tasks.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of Alzheimer’s diseases
The global Alzheimer's disease therapeutics market is growing due to the increasing prevalence of the disease, particularly in developed countries with higher life expectancies. This has led to a greater demand for effective treatment options, driving research and development in the field.
For instance, according to an article published in NCBI 2023, over 25 million people worldwide are affected by dementia, primarily Alzheimer's disease. The cause is still unknown, but evidence suggests that vascular risk factors and disorders, such as smoking, high blood pressure, obesity, diabetes, and cerebrovascular lesions, and psychosocial factors like education, social engagement, and physical exercise, may play a role in the pathogenetic process and clinical manifestation of dementia.
Long-term interventions focusing on controlling multiple vascular risk factors and maintaining socially integrated lifestyles and mentally stimulating activities are expected to reduce the risk or delay the clinical onset of dementia, including Alzheimer's disease.
Regulatory hurdles
The global Alzheimer's disease therapeutics market faces challenges such as high failure rates in clinical trials, the complexity of the disease, regulatory hurdles, and high costs. The lack of accessibility in low- and middle-income countries and the high cost of existing treatments further limit the market's growth, despite the increasing demand driven by the disease's prevalence.
Market Segment Analysis
The global Alzheimer’s disease therapeutics market is segmented based on drug class, route of administration, distribution channel, and region.
The cholinesterase inhibitors from the drug class segment accounted for approximately 43.3% of the alzheimer’s disease (AD) therapeutics market share
The cholinesterase inhibitors from the drug class segment accounted for approximately 43.3%. Cholinesterase inhibitors are a key component in the global Alzheimer's disease (AD) therapeutics market, enhancing cognitive function and memory in mild to moderate AD patients. These drugs, like donepezil, rivastigmine, and galantamine, increase acetylcholine levels, a neurotransmitter typically reduced in AD patients.
Although they do not cure the disease or halt its progression, they provide symptomatic relief, improving patient quality of life and easing caregiver burden. The global market for cholinesterase inhibitors is significant due to their efficacy, availability, and ongoing need for symptomatic AD management. However, the development of new, more effective therapies may impact their market share in the future.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to its high prevalence and access to excellent hospitals and research centers. The FDA and Health Canada ensure the safety and effectiveness of Alzheimer's drugs. The region's significant healthcare spending and support from patient-focused groups contribute to the overall success of Alzheimer's research and treatment.
For instance, in July 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Market Segmentation
By Drug Class
Cholinesterase Inhibitors
Donepezil
Galantamine
Rivastigmine
NMDA Receptor Antagonists
Manufactured Combination
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Eli Lilly and Company, Biogen Inc., AstraZeneca PLC, Roche Holding AG, Novartis International AG, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc., H. Lundbeck A/S among others.
Key Developments
In June 2024, Eisai and Biogen launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody "LEQEMBI" in China, approved in January 2024 for treating mild cognitive impairment due to Alzheimer's disease and mild AD dementia. China is the third country to launch LEQEMBI, following the United States and Japan.
Why Purchase the Report?
To visualize the global Alzheimer’s disease (AD) therapeutics market segmentation based on drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the Alzheimer’s disease (AD) therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global Alzheimer’s disease (AD) therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of Alzheimer’s Disease
4.1.1.2. Advancements in the treatment options
4.1.2. Restraints
4.1.2.1. Regulatory hurdles
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Cholinesterase Inhibitors *
6.2.1. Introduction
6.3. NMDA Receptor Antagonists
6.4. Manufactured Combination
6.5. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Eli Lilly and Company*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Biogen Inc.
11.3. AstraZeneca PLC
11.4. Roche Holding AG
11.5. Novartis International AG
11.6. Johnson & Johnson
11.7. Merck & Co., Inc.
11.8. Pfizer Inc.
11.9. Amgen Inc.
11.10. H. Lundbeck A/S (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, Biogen Inc., AstraZeneca PLC, Roche Holding AG, Novartis International AG, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Alzheimer's Disease Therapeutics Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Alzheimer's Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Alzheimer's Disease Therapeutics Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 6 Global Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 8 Global Alzheimer's Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Alzheimer's Disease Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)

Table 10 North America Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 11 North America Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 12 North America Alzheimer's Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 13 South America Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 14 South America Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 15 South America Alzheimer's Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 16 Europe Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 17 Europe Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 18 Europe Alzheimer's Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 19 Asia-Pacific Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 20 Asia-Pacific Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Alzheimer's Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 22 Middle East and Africa Alzheimer's Disease Therapeutics Market Value, By Stage, 2022-2033 (US$ Billion)

Table 23 Middle East and Africa Alzheimer's Disease Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 24 Middle East and Africa Alzheimer's Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 Eli Lilly and Company: Overview

Table 26 Eli Lilly and Company: Product Portfolio

Table 27 Eli Lilly and Company: Key Developments

Table 28 Pfizer Inc.: Overview

Table 29 Pfizer Inc.: Product Portfolio

Table 30 Pfizer Inc.: Key Developments

Table 31 Merck & Co., Inc.: Overview

Table 32 Merck & Co., Inc.: Product Portfolio

Table 33 Merck & Co., Inc.: Key Developments

Table 34 Eisai Co., Ltd.: Overview

Table 35 Eisai Co., Ltd.: Product Portfolio

Table 36 Eisai Co., Ltd.: Key Developments

Table 37 Merz Therapeutics: Overview

Table 38 Merz Therapeutics: Product Portfolio

Table 39 Merz Therapeutics: Key Developments

Table 40 Otsuka Pharmaceutical Co., Ltd.: Overview

Table 41 Otsuka Pharmaceutical Co., Ltd.: Product Portfolio

Table 42 Otsuka Pharmaceutical Co., Ltd.: Key Developments

Table 43 Alpha Cognition: Overview

Table 44 Alpha Cognition: Product Portfolio

Table 45 Alpha Cognition: Key Developments

Table 46 Johnson & Johnson Services, Inc.: Overview

Table 47 Johnson & Johnson Services, Inc.: Product Portfolio

Table 48 Johnson & Johnson Services, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 3 Global Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Alzheimer's Disease Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 5 Global Alzheimer's Disease Therapeutics Market Y-o-Y Growth, By Stage, 2023-2033 (%)

Figure 6 Predominantly Inattentive Presentation Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 7 Predominantly Hyperactive/Impulsive Presentation Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 8 Combined Presentation Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 9 Global Alzheimer's Disease Therapeutics Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 10 NMDA Receptor Antagonists Drug Class in Global Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 11 Combination Drugs Drug Class in Global Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 12 Immunotherapy Drug Class in Global Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 13 Others Drug Class in Global Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 14 Global Alzheimer's Disease Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 15 North America Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 16 North America Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 17 North America Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 18 North America Alzheimer's Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 19 South America Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 20 South America Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 21 South America Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 22 South America Alzheimer's Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 23 Europe Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 24 Europe Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 25 Europe Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 26 Europe Alzheimer's Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 27 Asia-Pacific Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 28 Asia-Pacific Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 29 Asia-Pacific Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 30 Asia-Pacific Alzheimer's Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 31 Middle East and Africa Alzheimer's Disease Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 32 Middle East and Africa Alzheimer's Disease Therapeutics Market Share, By Stage, 2024 & 2033 (%)

Figure 33 Middle East and Africa Alzheimer's Disease Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 34 Eli Lilly and Company: Financials

Figure 35 Pfizer Inc.: Financials

Figure 36 Merck & Co., Inc.: Financials

Figure 37 Eisai Co., Ltd.: Financials

Figure 38 Merz Therapeutics: Financials

Figure 39 Otsuka Pharmaceutical Co., Ltd.: Financials

Figure 40 Alpha Cognition: Financials

Figure 41 Johnson & Johnson Services, Inc.: Financials

세계 알츠하이머병(AD) 치료제 시장 – 2024-2031년

Global Alzheimer’s Disease (AD) Therapeutics Market - 2024-2031